NEW YORK, Dec. 8 Reportlinker.com announces that a new market research report is available in its catalogue:
Bulk Paclitaxel - A Global Update of Market Trends & Opportunities
Advertisement
http://www.reportlinker.com/p0164226/Bulk-Paclitaxel---A-Global-Update-of-Market-Trends--Opportunities.html
World bulk paclitaxel market stands enthused by the effervescent levels of research and development. With market participants injecting resources into developing unique paclitaxel formulations, emergence of new disease indications is expected to result in expanded market opportunities in the medium to long run. For instance, development of paclitaxel-coated coronary stents will help further improve the use and sales of paclitaxel. With patent expiries leading to the influx of generic forms of paclitaxel, competition is expected to intensify and result in price reductions.
Advertisement
These and other market data and trends are presented in "Bulk Paclitaxel: A Global Update of Market Trends & Opportunities" by BizAcumen, Inc. Our reports are designed to be most comprehensive in geographic coverage and vertical market analyses.
BULK PACLITAXEL BMR-1026
CONTENTS
1. METHODOLOGY 1
Study Reliability and Reporting Limitations 1
Disclaimers 2
Quantitative Techniques & Reporting Level 3
2. INDUSTRY OVERVIEW 3
Paclitaxel - Leading from the Front 3
US Market - Magnificently Outdistancing Others 4
Cancer Blockbusters - Facing the Brunt 4
A Sunrise Opportunity 4
BMS' Reign Comes to an End 4
Exploring New Avenues 5
Falling Prices - Boon for The Customers, Bane for The Companies 6
All the Strangle for Peanuts? 6
Factors Affecting the Market 6
Paclitaxel Versus Abraxane 7
3. OUTLOOK 7
Competitive Scenario 8
Cancer Generics - A Time for Optimism 8
The US Piazza 8
4. PRODUCT FACTS 9
5. RESEARCH AND DEVELOPMENT 10
Angiotech Unfurls New Dimensions for Paclitaxel 10
Clinical Research Favors Paclitaxel for Breast Cancer Treatment 11
American BioScience' Nab Technology Unveils Higher Tissue
Penetration Potential 11
Naturol Develops Unique Extraction Technology for Producing
Paclitaxel from Canadian Yew 11
Ivax Corp.'s Xorane Revolutionizes the Delivery of Paclitaxel 12
6. CORPORATE DEVELOPMENTS 13
Sonus to Merge with OncoGenex 13
Acusphere Signs Licensing Deal with Cephalon 13
Sonus Terminates TOCOSOL Paclitaxel Development Program 13
Eagle Pharmaceuticals to Develop and Market Tocosol Paclitaxel 13
Pliva Lachema Receives ANDA for Paclitaxel Injection 14
Cell Therapeutics Receives EMEA Acceptance 14
Abraxis Wins Approval for ABRAXANE in Korea 14
Boston Scientific Obtains Approval for TAXUS® Liberte® from
Health Canada 14
Cell Therapeutics Renames Xyotax as Opaxio 14
Dabur Launches Cancer Drug 14
Hospira Takes Over Mayne Pharma 14
Protherics to Acquire MacroMed 15
Abraxis Acquires Arizona Production Facility 15
Indena Inks Worldwide License Agreement with Spectrum Pharma 15
Bioxel Bags Major Paclitaxel Order 16
Bioxel Enters into Supply Agreement 16
Bioxel Bags Paclitaxel Supply Contract 16
Indena Establishes New Plant to Produce Synthetic Paclitaxel 16
Abraxis Selects Korean Green Cross to Market ABRAXANE® 17
Abraxis Grants License to Biocon for Marketing ABRAXANE® 17
Bioxel Registers Docetaxel with US FDA 17
Bayer Quashes TOCOSOL Paclitaxel License with Sonus 17
Abraxis' ABRAXANE Convinces European CHMP 18
Abraxis Receives Approval for ABRAXANE in Australia 18
Eurocor Receives CE Mark 18
SuperGen Divests Certain Drugs to Intas 18
Abraxis Plans Separation of Oncology Business 18
Dabur Introduces Nanoxel 19
7. MAJOR PLAYERS 19
Abraxis BioScience, Inc. (USA) 19
Bristol-Myers Squibb Co. (USA) 19
Hospira, Inc. (USA) 20
Indena S.p.A. (Italy) 20
OncoGenex Pharmaceuticals, Inc. (USA) 20
Teva Pharmaceuticals USA, Inc. (USA) 20
8. MARKET ANALYTICS 21
9. THE UNITED STATES 22
Rising Demand for Paclitaxel 23
Alarming Growth of Breast Cancer 23
Clinical Research Favors Paclitaxel for Breast Cancer Treatment 23
Paclitaxel - An Important Element 23
Corporate Talk 23
Drug-Eluting Stents - Marching Ahead 24
10. REST OF WORLD 25
Europe 25
European Market Overview 25
European Market Battling Cost- Containment Woes 25
Efforts to Improve the Scenario and their Effect on
Paclitaxel Market 26
China 26
Chinese Government Strategizing to Save Paclitaxel Reserves 26
EXHIBITS
Table 1: Global Bulk Paclitaxel Market by Region for the Period
2007-2015 (Sales in Kilograms)
Table 2: Percentage Breakdown (Volume Sales) of Global Bulk
Paclitaxel Market by Region for the Years 2008 & 2012
Table 3: Global Bulk Paclitaxel Market by Region for the
Period 2007-2015 (Sales in US$ Million)
Table 4: Percentage Breakdown (Dollar Sales) of Global Bulk
Paclitaxel Market by Region for the Years 2008 & 2012
Table 5: Bulk Paclitaxel Market in the US: 2007-2015 (Sales in
Kilograms)
Table 6: Bulk Paclitaxel Market in the US: 2007-2015 (Sales
in US$ Million)
Table 7: Bulk Paclitaxel Market in Rest of World: 2007-2015
(Sales in Kilograms)
Table 8: Bulk Paclitaxel Market in Rest of World: 2007-2015
(Sales in US$ Million)
COMPANIES PROFILED
To order this report:
Pharmaceutical Industry: Bulk Paclitaxel - A Global Update of Market Trends & Opportunities
More Market Research Report
Nicolas BombourgReportlinkerEmail: [email protected]: (805)652-2626Intl: +1 805-652-2626
SOURCE Reportlinker
